EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study

Caroline Buck, Francisco Brenes Castillo, Elena Bettio, Joanne Land, Orla McCourt, Helen Poole, Rachel Tarling, Kwee Yong, Rakesh Popat, Lydia Lee, Annabel McMillan, Xenofon Papanikolaou und 6 weitere

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08663-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Caroline Buck und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Epidemiology and Health, University College London, London, UK. caroline.buck@ucl.ac.uk. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Qualitative Research. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Continuous lenalidomide maintenance treatment after autologous stem cell transplantation delivers improvement in progression free and overall survival among newly diagnosed multiple myeloma patients and has been the standard of care in the UK since March 2021. However, there is scant information about its impact on patients’ day-to-day lives. This service evaluation aimed to qualitatively assess patients receiving lenalidomide treatment at a cancer centre in London, in order that the service might better align with needs and expectations of patients.

Methods

We conducted 20 semi-structured interviews among myeloma patients who were on continuous lenalidomide maintenance treatment at a specialist cancer centre in London. Members of the clinical team identified potentially eligible participants to take part, and convenience sampling was used to select 10 male and 10 female patients, median age of 58 (range, 45–71). The median treatment duration was 11 months (range, 1–60 months). Participants were qualitatively interviewed following the same semi-structured interview guide, which was designed to explore patient experience and insights of lenalidomide. Reflexive thematic analysis was used for data analysis.

Results

Four overarching themes were as follows: (i) lenalidomide: understanding its role and rationale; (ii) reframing the loss of a treatment-free period to a return to normal life; (iii) the reality of being on lenalidomide: balancing hopes with hurdles; (iv) gratitude and grievances: exploring mixed perceptions of care and communication. Results will be used to enhance clinical services by tailoring communication to better meet patients’ preferences when making treatment decisions.

Conclusion

This study highlights that most patients feel gratitude for being offered continuous lenalidomide and perceive it as alleviating some fears concerning relapse. It reveals variations in side effects in different age groups; younger patients reported no/negligible side effects, whilst several older patients with comorbidities described significant symptom burden, occasionally leading to treatment discontinuation which caused distress at the perceived loss of prolonged remission. Future research should prioritise understanding the unique needs of younger patients living with multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideQualitative ResearchHumansMaleFemaleMiddle AgedAgedLondonMaintenance ChemotherapyInterviews as TopicQuality of LifeTransplantation, AutologousAntineoplastic Agents

Stichwörter der Autor:innen

LenalidomideMaintenanceMultiple MyelomaQualitative

Substanzen

LenalidomideAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Epidemiology and Health, University College London, London, UK. caroline.buck@ucl.ac.uk.
  • Institute of Epidemiology and Health, University College London, London, UK.
  • Haematology Department, University College London Hospital, London, UK.
  • Research Department of Haematology, UCL Cancer Institute, University College London, London, UK.
  • School of Psychology, Liverpool John Moores University, Liverpool, UK.

Zitieren

APA

Buck, C., Brenes Castillo, F., Bettio, E., Land, J., McCourt, O., Poole, H., Tarling, R., Yong, K., Popat, R., Lee, L., McMillan, A., Papanikolaou, X., Xu, K., Kyriakou, C., Rabin, N., Wechalekar, A., Fisher, A., & Sive, J. (2024). The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08663-4

Vancouver

Buck C, Brenes Castillo F, Bettio E, Land J, McCourt O, Poole H, et al. The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08663-4

BibTeX
@article{Buck2024,
  author = {Buck, Caroline and Brenes Castillo, Francisco and Bettio, Elena and Land, Joanne and McCourt, Orla and Poole, Helen and Tarling, Rachel and Yong, Kwee and Popat, Rakesh and Lee, Lydia and McMillan, Annabel and Papanikolaou, Xenofon and Xu, Ke and Kyriakou, Chara and Rabin, Neil and Wechalekar, Ashu and Fisher, Abigail and Sive, Jonathan},
  title = {The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08663-4}
}
Kostenlos starten →